Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Wajnberg, Ania, Amanat, Fatima, Firpo, Adolfo, Altman, Deena R., Bailey, Mark J., Mansour, Mayce, McMahon, Meagan, Meade, Philip, Mendu, Damodara Rao, Muellers, Kimberly, Stadlbauer, Daniel, Stone, Kimberly, Strohmeier, Shirin, Simon, Viviana, Aberg, Judith, Reich, David L., Krammer, Florian, Cordon-Cardo, Carlos·2020·Science
DOI 10.1126/science.abd7728

Cited by (1,007)

Items 201–300 of 1,007

  1. Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications
    Endeshaw Chekol Abebe, Tadesse Asmamaw Dejenie · 2023 · Frontiers in Immunology
  2. Reconstructing the course of the COVID-19 epidemic over 2020 for US states and counties: Results of a Bayesian evidence synthesis model
    Melanie H. Chitwood, Marcus Russi, Kenneth S. Gunasekera, Joshua Havumaki, Fayette Klaassen, Virginia E. Pitzer, Joshua A. Salomon, Nicole A. Swartwood, Joshua L. Warren, Daniel M. Weinberger et al. · 2022 · PLoS Computational Biology
  3. SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19
    Vivian Glück, Sonja Grobecker, Leonid Tydykov, Bernd Salzberger, Thomas Glück, Tanja Weidlich, Manuela Bertok, Christine Gottwald, Jürgen J. Wenzel, André Gessner et al. · 2021 · Infection
  4. Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity
    Benjamin T. Bradley, Andrew B Bryan, Susan L. Fink, Erin A. Goecker, Pavitra Roychoudhury, Meei-Li W. Huang, Haiying Zhu, Anu Chaudhary, Bhanupriya Madarampalli, Joyce Lu et al. · 2021 · Journal of Clinical Microbiology
  5. Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes
    Tyll Krueger, Krzysztof Gogolewski, Marcin Bodych, Anna Gambin, Giulia Giordano, Sarah Cuschieri, Thomas Czypionka, Matjaž Perc, Elena Petelos, Magdalena Rosińska et al. · 2022 · Communications Medicine
  6. Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey
    Michael D. Swartz, Stacia M. DeSantis, Ashraf S. Yaseen, Frances A. Brito, Melissa A. Valerio-Shewmaker, Sarah Elizabeth Messiah, Luis León‐Novelo, Harold Willis Kohl, Cesar Leonardo Pinzon-Gomez, Tianyao Hao et al. · 2022 · The Journal of Infectious Diseases
  7. Kinetics of Anti–SARS-CoV-2 IgG Antibodies in Hemodialysis Patients Six Months after Infection
    Hamza Sakhi, Djamal Dahmane, Philippe Attias, Thomas Kofman, Magali Bouvier‐Alias, Nathanaël Lapidus, Slim Fourati, Khalil El Karoui, Mondor NephroCov Study Group · 2021 · Journal of the American Society of Nephrology
  8. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection
    Julien Favresse, Christine Eucher, Marc Elsen, Constant Gillot, Sandrine Van Eeckhoudt, Jean‐Michel Dogné, Jonathan Douxfils · 2021 · Microorganisms
  9. A behavioural modelling approach to assess the impact of COVID-19 vaccine hesitancy
    Bruno Buonomo, Rossella Della Marca, Alberto d’Onofrio, Maria Groppi · 2021 · Journal of Theoretical Biology
  10. IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection
    Hari Ram Choudhary, Debaprasad Parai, Girish Chandra Dash, Annalisha Peter, Subrat Kumar Sahoo, Matrujyoti Pattnaik, Usha Kiran Rout, Rashmi Ranjan Nanda, Sanghamitra Pati, Debdutta Bhattacharya · 2021 · Infection
  11. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals
    Alena J. Markmann, Natasa Giallourou, Debarshi Ryan Bhowmik, Yixuan Jacob Hou, Aaron Lerner, David R. Martinez, Lakshmanane Premkumar, Heather B. Root, David van Duin, Sonia Napravnik et al. · 2021 · mSphere
  12. The way of SARS-CoV-2 vaccine development: success and challenges
    Yetian Dong, Tong Dai, Bin Wang, Lei Zhang, Linghui Zeng, Jun Huang, Haiyan Yan, Long Zhang, Fangfang Zhou · 2021 · Signal Transduction and Targeted Therapy
  13. The prevalence of adaptive immunity to COVID-19 and reinfection after recovery – a comprehensive systematic review and meta-analysis
    Tawanda Chivese, Joshua T. Matizanadzo, Omran A. H. Musa, George Hindy, Luis Furuya‐Kanamori, Nazmul Islam, Rafal Al-Shebly, Rana Shalaby, Mohammad Habibullah, Talal A. Al-Marwani et al. · 2022 · Pathogens and Global Health
  14. Delivery Routes for COVID-19 Vaccines
    Jang Hyun Park, Heung Kyu Lee · 2021 · Vaccines
  15. SARS-CoV-2 Seroprevalence in Household Domestic Ferrets (Mustela putorius furo)
    Jacobo Giner, Sergio Villanueva‐Saz, Ana Pilar Tobajas, María Dolores Pérez, Ana Isabel González, Maite Verde, Andrés Yzuel, Ana García‐García, Víctor Taleb, Erandi Lira‐Navarrete et al. · 2021 · Animals
  16. Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities
    Maria Gabriela Noval, Maria E. Kaczmarek, Akiko Koide, Bruno A. Rodriguez-Rodriguez, Ping Louie, Takuya Tada, Takamitsu Hattori, Tatyana Panchenko, Larizbeth A. Romero, Kai Wen Teng et al. · 2021 · Scientific Reports
  17. Comprehensive analysis of SARS‐CoV‐2 antibody dynamics in New Zealand
    Alana L. Whitcombe, Reuben McGregor, Alyson Craigie, Alex James, Richard Charlewood, Natalie Lorenz, James M. J. J. Dickson, Campbell R. Sheen, Barbara Koch, Shivani Fox‐Lewis et al. · 2021 · Clinical & Translational Immunology
  18. Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2
    Louis Grandjean, Anja Saso, Arturo Torres Ortiz, Tanya Lam, James Hatcher, Rosie Thistlethwayte, Mark Harris, Timothy Best, Marina Johnson, Helen R. Wagstaffe et al. · 2021 · Clinical Infectious Diseases
  19. SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection
    Yan Zhan, Yufang Zhu, Shanshan Wang, Shijun Jia, Yunling Gao, Yingying Lü, Cai-Li Zhou, Ran Liang, Dingwen Sun, Xiaobo Wang et al. · 2021 · Signal Transduction and Targeted Therapy
  20. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people
    Tara M. Narowski, Kristin Raphel, Lily E. Adams, Jenny Huang, Nadja A. Vielot, Ramesh Jadi, Aravinda M. de Silva, Ralph Steven Baric, John Lafleur, Lakshmanane Premkumar · 2022 · Cell Reports
  21. Cerebrovascular Complications of COVID-19 and COVID-19 Vaccination
    Manuela De Michele, Joshua Kahan, Irene Berto, Oscar G. Schiavo, Marta Iacobucci, Danilo Toni, Alexander Eliot Merkler · 2022 · Circulation Research
  22. Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection
    Asgar Ansari, Rakesh Kumar Arya, Shilpa Sachan, Someshwar Nath Jha, Anurag Kalia, Anupam Lall, Alessandro Sette, Alba Grifoni, Daniela Weiskopf, Poonam Coshic et al. · 2021 · Frontiers in Immunology
  23. Mild SARS-CoV-2 Infections and Neutralizing Antibody Titers
    Francesco Bonfante, Paola Costenaro, Anna Cantarutti, Costanza Di Chiara, Alessio Bortolami, Maria Raffaella Petrara, Francesco Carmona, Matteo Pagliari, Chiara Cosma, Sandra Cozzani et al. · 2021 · PEDIATRICS
  24. Persistent Lung Injury and Prothrombotic State in Long COVID
    Mengqi Xiang, Haijiao Jing, Chengyue Wang, Valerie Anne Novakovic, Jialan Shi · 2022 · Frontiers in Immunology
  25. Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster
    Marco Brustolin, Jordi Rodon, Maria Luisa Rodrı́guez de la Concepción, Carlos Ávila‐Nieto, Guillermo Cantero, Mónica Pérez, Nigeer Te, Marc Noguera-Julián, Vı́ctor Guallar, Alfonso Valencia et al. · 2021 · Emerging Microbes & Infections
  26. Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020)
    David S. Kim, Sarah Rowland‐Jones, Ester Gea‐Mallorquí · 2020 · Frontiers in Immunology
  27. Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents
    Carolina Garrido, Jillian H. Hurst, Cynthia G. Lorang, Jhoanna N. Aquino, Javier Rodriguez, Trevor S. Pfeiffer, Tulika Singh, Eleanor C. Semmes, Debra J. Lugo, Alexandre Tellechea Rotta et al. · 2021 · JCI Insight
  28. The association between obesity and peak antibody titer response in COVID‐19 infection
    Soffer, Shelly, Glicksberg, Benjamin S., Zimlichman, Eyal, Efros, Orly, Levin, Matthew A., Freeman, Robert, Reich, David L., Klang, Eyal · 2021 · Obesity
  29. Vaccination versus infection with SARS‐CoV‐2: Establishment of a high avidity IgG response versus incomplete avidity maturation
    Friedhelm Struck, Patrick A. Schreiner, Eva Staschik, Karin Wochinz‐Richter, Sarah Schulz, Erwin Soutschek, Manfred Motz, Georg Bauer · 2021 · Journal of Medical Virology
  30. Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection
    Hongyan Hou, Yandi Zhang, Guoxing Tang, Ying Luo, Wei Liu, Chang Cheng, Yuhuan Jiang, Zhigang Xiong, Shiji Wu, Ziyong Sun et al. · 2021 · Journal of Allergy and Clinical Immunology
  31. The complexities of SARS-CoV-2 serology
    Catherine F. Houlihan, Rupert C. L. Beale · 2020 · The Lancet Infectious Diseases
  32. COVID-19: systemic pathology and its implications for therapy
    Qi Shen, Jie Li, Zhan Zhang, Shuang Guo, Qiuhong Wang, Xiaorui An, Haocai Chang · 2021 · International Journal of Biological Sciences
  33. Symptoms Compatible With Long Coronavirus Disease (COVID) in Healthcare Workers With and Without Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection—Results of a Prospective Multicenter Cohort
    Carol Strahm, Marco Seneghini, Sabine Güsewell, Thomas Egger, Onicio Batista Leal-Neto, Angela Brucher, Eva Lemmenmeier, Dorette Meier Kleeb, Jens Carsten Möller, Philip Rieder et al. · 2022 · Clinical Infectious Diseases
  34. Distorted chemosensory perception and female sex associate with persistent smell and/or taste loss in people with SARS-CoV-2 antibodies: a community based cohort study investigating clinical course and resolution of acute smell and/or taste loss in people with and without SARS-CoV-2 antibodies in London, UK
    Janine Makaronidis, Chloe Firman, Cormac G. Magee, Jessica Mok, Nyaladzi Balogun, Matt Lechner, Alisia Carnemolla, Rachel Louise Batterham · 2021 · BMC Infectious Diseases
  35. Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance
    Perez-Saez, Javier, Zaballa, María-Eugenia, Yerly, Sabine, Andrey, Diego O., Meyer, Benjamin, Eckerle, Isabella, Balavoine, Jean-François, Chappuis, François, Pittet, Didier, Trono, Didier et al. · 2021 · Clinical Microbiology and Infection
  36. Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey
    Portia Chipo Mutevedzi, Mary Kawonga, Gaurav Kwatra, Andrew Moultrie, Vicky Lynne Baillie, Nicoletta Mabena, Masego Nicole Mathibe, Martin Mosotho Rafuma, Innocent Maposa, Geoff Abbott et al. · 2021 · International Journal of Epidemiology
  37. Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19
    Juan G. Ripoll, Noud van Helmond, Jonathon W. Senefeld, Chad C. Wiggins, Stephen A. Klassen, Sarah E. Baker, Kathryn F. Larson, Brenna M. Murphy, Kylie J. Andersen, Shane K. Ford et al. · 2021 · Clinical Microbiology Newsletter
  38. SARS-CoV-2 Antigens Expressed in Plants Detect Antibody Responses in COVID-19 Patients
    Mohau S. Makatsa, Marius Belmondo Tincho, Jerome M. Wendoh, Sherazaan D. Ismail, Rofhiwa Nesamari, Francisco F. P. G. Pêra, S Beer, Anura David, Sarika Jugwanth, Maemu Petronella Gededzha et al. · 2021 · Frontiers in Plant Science
  39. Protective neutralizing epitopes in SARS‐CoV‐2
    Hejun Liu, Ian A. Wilson · 2022 · Immunological Reviews
  40. Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC
    Hyunah Yoon, Rachel M. Bartash, Inessa Gendlina, Johanna Rivera, Antonio S. Nakouzi, Robert H. Bortz, Ariel S. Wirchnianski, Monika Paroder, Karen Fehn, Leana Serrano‐Rahman et al. · 2021 · JCI Insight
  41. Immunity to SARS-CoV-2: Lessons Learned
    JAIME E. FERGIE, Amit K. Srivastava · 2021 · Frontiers in Immunology
  42. Increased 1-year mortality in haemodialysis patients with COVID-19: a prospective, observational study
    Sol M. Carriazo, Sebastián Mas, Clara Seghers, Jaime Cano, Elena Gomá-Garcés, Alejandro Avello, Alberto Ortíz, Emilio González‐Parra · 2021 · Clinical Kidney Journal
  43. SARS-CoV-2 infections among healthcare workers at Helsinki University Hospital, Finland, spring 2020: Serosurvey, symptoms and risk factors
    Anu Kantele, Tinja Lääveri, Lauri Kareinen, Sari H. Pakkanen, Karin Blomgren, Sointu Mero, Anu Patjas, Jenni M. E. Virtanen, Ruut Uusitalo, Maija Lappalainen et al. · 2020 · Travel Medicine and Infectious Disease
  44. SARS‐CoV ‐2 antibody persistence in COVID ‐19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance
    Clara Di Germanio, Graham Simmons, Kathleen K. Kelly, Rachel Martinelli, Orsolya Darst, Mahzad Azimpouran, Mars Stone, Kelsey E. Hazegh, Eduard Grebe, Shuting Zhang et al. · 2021 · Transfusion
  45. Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests.
    Isabel Montesinos, Hafid Dahma, Fleur Wolff, Nicolás Dauby, Sabrina Delaunoy, Magaly Wuyts, Cedric Detemmerman, Cécile Duterme, Olivier Vandenberg, Charlotte Martin et al. · 2021 · Journal of Clinical Virology
  46. Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
    Ane Ogbe, Matthew J. Pace, Mustapha Bittaye, Timothy Tipoe, Sandra Adele, Jasmini Alagaratnam, Parvinder K. Aley, M. Azim Ansari, Anna Bara, Samantha Broadhead et al. · 2022 · JCI Insight
  47. SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection
    Sebastian Havervall, August Jernbom Falk, Jonas Klingström, Henry Ng, Nina Greilert‐Norin, Lena Gabrielsson, Ann‐Christin Salomonsson, Eva Isaksson, Ann‐Sofie Rudberg, Cecilia Hellström et al. · 2022 · PLoS ONE
  48. Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection
    Janeri Fröberg, Dimitri Adriaan Diavatopoulos · 2021 · Current Opinion in Infectious Diseases
  49. COVID ‐19 and plasma cells: Is there long‐lived protection?*
    Doan C. Nguyen, Pedro A. Lamothe, Matthew Charles Woodruff, Ankur Singh Saini, Caterina Elisa Faliti, Igñacio Sanz, Frances Eun-Hyung Lee · 2022 · Immunological Reviews
  50. SARS-CoV-2—The Role of Natural Immunity: A Narrative Review
    Sara Diani, Erika A. Leonardi, Attilio Cavezzi, Simona Ferrari, Oriana Iacono, Alice Limoli, Zoe Bouslenko, Daniele Natalini, Stefania Conti, Mauro Mantovani et al. · 2022 · Journal of Clinical Medicine
  51. Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia
    Stefania Dispinseri, Vito Lampasona, Massimiliano Secchi, Andrea Cara, Elena Bazzigaluppi, Donatella R. M. Negri, Cristina Brigatti, Maria Franca Pirillo, Ilaria Marzinotto, Martina Borghi et al. · 2021 · The Journal of Clinical Endocrinology & Metabolism
  52. Justice in COVID-19 vaccine prioritisation: rethinking the approach
    Rosamond Rhodes · 2021 · Journal of Medical Ethics
  53. Decline in neutralising antibody responses, but sustained T‐cell immunity, in COVID‐19 patients at 7 months post‐infection
    Jun Chen, Xiaomin Liu, Xinyu Zhang, Yixiao Lin, Danping Liu, Jingna Xun, Zhenyan Wang, Ling Gu, Qian Li, Dan Yin et al. · 2021 · Clinical & Translational Immunology
  54. Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation
    Lauren M. Meyers, Andrés H. Gutiérrez, Christine Boyle, Frances E. Terry, Bethany McGonnigal, Andres Μ. Salazar, Michael F. Princiotta, Wiliam D. Martin, Anne Searls De Groot, Leonard Moise · 2021 · npj Vaccines
  55. Peculiarities of the T Cell Immune Response in COVID-19
    Dmitry Anatolievich Kudlay, И.А. Кофиади, Musa Rakhimovich Khaitov · 2022 · Vaccines
  56. Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection
    Serena Marchi, Simonetta Viviani, Edmond J. Remarque, Antonella Ruello, Emilio Bombardieri, Valentina Bollati, Gregorio Paolo Milani, Alessandro Manenti, Giulia Lapini, Annunziata Rebuffat et al. · 2021 · PLoS ONE
  57. Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI
    Raul Pellini, Aldo Venuti, Fulvia Pimpinelli, Elva Abril, Giovanni Blandino, Flaminia Campo, Laura Conti, Armando DE VIRGILIO, Federico De Marco, Enea Gino Di Domenico et al. · 2021 · Vaccines
  58. COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men
    Alexis R. Demonbreun, Amelia Sancilio, Matt E. Velez, Daniel T. Ryan, Lorenzo L. Pesce, Rana Saber, Lauren A. Vaught, Nina L. Reiser, Ryan R. Hsieh, Richard T. D’Aquila et al. · 2021 · The Journal of Infectious Diseases
  59. Risk factor targeting for vaccine prioritization during the COVID-19 pandemic
    Lloyd A. C. Chapman, Poojan D. Shukla, Isabel Rodríguez-Barraquer, Priya B. Shete, Tomás M. León, Kirsten B. Bibbins-Domingo, George Williams Rutherford, Robert Schechter, Nathan C. Lo · 2022 · Scientific Reports
  60. Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR
    Megan Catherine Schwarz, Denis Torre, Daniel Lozano‐Ojalvo, Anthony Tanoto Tan, Tommaso Tabaglio, Slim Mzoughi, Rodrigo Sánchez-Tarjuelo, Nina Le Bert, Joey Ming Er Lim, Sandra Hatem et al. · 2022 · Nature Biotechnology
  61. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis
    R. Goupil, M. Benlarbi, W. Beaubien-Souligny, Annie-Claire Nadeau-Fredette, D. Chatterjee, G. Goyette, L. Gunaratnam, Caroline Lamarche, A. Tom, A. Finzi et al. · 2021 · Canadian Medical Association Journal
  62. The Bone Marrow as Sanctuary for Plasma Cells and Memory T-Cells: Implications for Adaptive Immunity and Vaccinology
    Stefan Slamanig, Martijn A. Nolte · 2021 · Cells
  63. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein
    Hongyue Li, Yuhang Zhang, Dong Li, Yong‐Qiang Deng, Hongde Xu, Chaoyue Zhao, Jiandong Liu, Dan Wen, Jianguo Zhao, Yongchun Li et al. · 2021 · Signal Transduction and Targeted Therapy
  64. Projecting the SARS-CoV-2 transition from pandemicity to endemicity: Epidemiological and immunological considerations
    Lily Cohen, David J. Spiro, Cecile G. Viboud · 2022 · PLoS Pathogens
  65. Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines
    Astrid Korning Hvidt, Eva Anna Marianne Baerends, Ole Schmeltz Søgaard, Nina Breinholt Stærke, Dorthe Raben, Joanne Reekie, Henrik Nielsen, Işık Somuncu Johansen, Lothar Wiese, Thomas Benfield et al. · 2022 · Frontiers in Medicine
  66. Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum
    Sebastian Fiedler, Monika A. Piziorska, Viola Denninger, Alexey S. Morgunov, Alison Ilsley, Anisa Y. Malik, Matthias M. Schneider, Sean R. A. Devenish, Georg Meisl, Vasilis Kosmoliaptsis et al. · 2021 · ACS Infectious Diseases
  67. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Ligong Lu, Hui Zhang, Meixiao Zhan, Jun Jiang, Hua Yin, Danielle J. Dauphars, Shi-You Li, Yong Li, You-Wen He · 2020 · Science China Life Sciences
  68. ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions
    Daniel J. Rawle, Thuy T. Le, Troy D. Dumenil, Kexin Yan, Bing Tang, Wilson Nguyen, Daniel Watterson, Naphak Modhiran, Jody Hobson‐Peters, Cameron Bishop et al. · 2021 · PLoS Pathogens
  69. Ultrasensitive Measurement of Both SARS-CoV-2 RNA and Antibodies from Saliva
    Dmitry Ter‐Ovanesyan, Tal Gilboa, Roey Lazarovits, Alexandra Rosenthal, Xu G. Yu, Jonathan Z. Li, George McDonald Church, David R. Walt · 2021 · Analytical Chemistry
  70. Comparison of six commercially available SARS-CoV-2 antibody assays—Choice of assay depends on intended use
    Anna Christine Nilsson, Dorte Kinggaard Holm, Ulrik Stenz Justesen, Thøger Gorm-Jensen, Nanna Skaarup Andersen, Anne Lindebo Holm Øvrehus, Işık Somuncu Johansen, Jens Michelsen, Ulrik Sprogøe, Søren Thue Lillevang · 2020 · International Journal of Infectious Diseases
  71. Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab
    Chiara M. Cattaneo, Valeria Cancelli, Luisa Imberti, Kerry Dobbs, Alessandra Sottini, Chiara Pagani, Angelo Belotti, Alessandro Re, A. Anastasia, Virginia Quaresima et al. · 2021 · Blood Cancer Journal
  72. Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort
    Alexandra Rockstroh, Johannes Wolf, Jasmin Fertey, Sven Kalbitz, Stefanie Schroth, Christoph Lübbert, Sebastian Ulbert, Stephan Borte · 2021 · Emerging Microbes & Infections
  73. Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination
    Cho, Alice, Muecksch, Frauke, Schaefer-Babajew, Dennis, Wang, Zijun, Finkin, Shlomo, Gaebler, Christian, Ramos, Victor, Cipolla, Melissa, Mendoza, Pilar, Agudelo, Marianna et al. · 2021
  74. Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults
    Alejo Erice, David Varillas‐Delgado, Cristina Caballero · 2021 · Clinical Microbiology and Infection
  75. mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants
    Yunkai Yu, Dominic Esposito, Zhigang Kang, Jianming Lü, Alan Thomas Remaley, Valeria De Giorgi, Leonard N. Chen, Kamille A. West, Liang Cao · 2022 · Scientific Reports
  76. Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study
    Houda Amellal, Najlaa Assaid, Hicham Charoute, Khadija Akarid, Abderrahmane Maaroufi, Sayeh Ezzikouri, M’hammed Sarih · 2023 · PLoS ONE
  77. Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients
    A. Marcos, Magdalena Salcedo, Roberto Alonso, Manuel Rodríguez‐Perálvarez, María Olmedo, Javier Graus Morales, Valentín Cuervas‐Mons, Alba Cachero, Carmelo Loinaz, Mercedes Iñarrairaegui et al. · 2021 · American Journal of Transplantation
  78. Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity
    Stuart G. Tangye, Laurent Abel, Salah Al-Muhsen, Alessandro Aiuti, Saleh Al‐Muhsen, Fahd Al‐Mulla, Mark Stuart Anderson, Evangelos Andreakos, Antonio Novelli, Andrés Augusto Arias et al. · 2022 · Journal of Allergy and Clinical Immunology
  79. Dynamic Characteristic Analysis of Antibodies in Patients With COVID-19: A 13-Month Study
    Danrong Shi, Tian-Hao Weng, Jie Wu, Chunyan Dai, Rui Luo, Keda Chen, Miaojin Zhu, Xiangyun Lu, Linfang Cheng, Qiuqiang Chen et al. · 2021 · Frontiers in Immunology
  80. Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences
    Alessandra Aiello, Saeid Najafi Fard, Delia Goletti · 2023 · Frontiers in Immunology
  81. SARS-CoV-2 immunity in animal models
    Zhao Chen, Yaochang Yuan, Qing‐Tao Hu, Airu Zhu, Fenghua Chen, Shu Li, Xin Guan, Chao Lv, Tian Tang, Yiyun He et al. · 2024 · Cellular and Molecular Immunology
  82. Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients
    Varun K. Phadke, Nicholas Scanlon, Stanley C. Jordan, Nadine Rouphael · 2021 · Current Transplantation Reports
  83. Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group
    Helena Linardou, Nikolaos Spanakis, Georgia-Angeliki Koliou, Athina N. Christopoulou, Sofia Karageorgopoulou, Nephely Alevra, Anastasios Vagionas, Nikolaos Tsoukalas, Stavroula Sgourou, Elena Fountzilas et al. · 2021 · Cancers
  84. Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England
    Thomas Mason, Matt Whitston, Jack Hodgson, Ruth Watkinson, Yiu‐Shing Lau, Omnia Abdulrazeg, Matt Sutton · 2021 · BMC Medicine
  85. Protective Immunity after Natural Infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) – Kentucky, USA, 2020
    Kevin B. Spicer, Connor Glick, Alyson M. Cavanaugh, Douglas A. Thoroughman · 2021 · International Journal of Infectious Diseases
  86. Long-Term Analysis of Antibodies Elicited by Sputnik V in Tucuman, Argentina
    Rossana Elena Chahla, Rodrigo Hernán Tomas‐Grau, Silvia I. Cazorla, Diego Ploper, Esteban Vera Pingitore, Mónica Aguilar López, Patricia Aznar, María Elena Alcorta, Eva María del Mar Vélez, Agustín Stagnetto et al. · 2021 · The Lancet Regional Health - Americas
  87. Technical considerations to development of serological tests for SARS-CoV-2
    Emilie Ernst, Patricia Wolfe, Corrine M. Stahura, Katie A. Edwards · 2020 · Talanta
  88. Seropositivity in blood donors and pregnant women during the first year of SARS‐CoV‐2 transmission in Stockholm, Sweden
    Xaquín Castro Dopico, Sandra Muschiol, Murray Christian, Leo Hanke, Daniel J. Sheward, Nastasiya F. Grinberg, Joanna Rorbach, Gordana Bogdanović, Gerald M. McInerney, Tobias Allander et al. · 2021 · Journal of Internal Medicine
  89. A surrogate virus neutralization test to quantify antibody-mediated inhibition of SARS-CoV-2 in finger stick dried blood spot samples
    Amelia Sancilio, Richard T. D’Aquila, Elizabeth M. McNally, Matthew P. Velez, Michael G. Ison, Alexis R. Demonbreun, Thomas W. McDade · 2021 · Scientific Reports
  90. Efficacy and Safety of an Inactivated Whole-Virion Vaccine Against COVID-19, QazCovid-in®, In Healthy Adults: A Multicentre, Randomised, Single-Blind, Placebo-Controlled Phase 3 Clinical Trial With a 6-Month Follow-Up
    Berik M. Khairullin, Kunsulu D. Zakarya, Mukhit B. Orynbayev, Yergali O. Abduraimov, Markhabat Kassenov, Gulbanu Sarsenbayeva, Kulyaisan T. Sultankulova, Olga V. Chervyakova, Balzhan Sh. Myrzakhmetova, Наханов Азиз Куралбаевич et al. · 2022 · EClinicalMedicine
  91. Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection
    Gallais, Floriane, Gantner, Pierre, Bruel, Timothée, Velay, Aurelie, Planas, Delphine, Wendling, Marie-Josée, Bayer, Sophie, Solis, Morgane, Laugel, Elodie, Reix, Nathalie et al. · 2021
  92. SARS-CoV-2 Tests: Bridging the Gap between Laboratory Sensors and Clinical Applications
    Nikita Aleksandrovich Toropov, Eleanor L. Osborne, Lovleen Tina Joshi, James Davidson, Caitlin Morgan, Joseph William Page, Justin Pepperell, Frank Vollmer · 2021 · ACS Sensors
  93. Does the EU COVID Digital Certificate Strike a Reasonable Balance between Mobility Needs and Public Health?
    Gianluca Montanari Vergallo, Simona Zaami, F Negro, Pietro Brunetti, Alessandro DEL RIO, Enrico Marinelli · 2021 · Medicina
  94. Divergent trajectories of antiviral memory after SARS-CoV-2 infection
    Adriana Tomić, Donal Skelly, Ane Ogbe, Daniel O’Connor, Matthew J. Pace, Emily Adland, Frances Alexander, Mohammad Ali, Kirk Allott, M. Azim Ansari et al. · 2022 · Nature Communications
  95. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients
    Jira Chansaenroj, Ritthideach Yorsaeng, Jiratchaya Puenpa, Nasamon Wanlapakorn, Chintana Chirathaworn, Natthinee Sudhinaraset, Manit Sripramote, Piti Chalongviriyalert, Supunee Jirajariyavej, Phatharaporn Kiatpanabhikul et al. · 2022 · PLoS ONE
  96. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data
    Dung V. Nguyen, Peter Simmonds K, Maurice Steenhuis, Elise Wouters, Daniel J.-M. Desmecht, Mutien‐Marie Garigliany, Márta Romano, Cyril Barbezange, Piet Maes, Bram Van Holm et al. · 2021 · Eurosurveillance
  97. Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection
    Puya Dehgani‐Mobaraki, Asiya Kamber Zaidi, Nidhi Yadav, A. Floridi, Emanuela Floridi · 2021 · Clinical Immunology
  98. Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel
    Vivian Glück, Sonja Grobecker, Josef Köstler, Leonid Tydykov, Manuela Bertok, Tanja Weidlich, Christine Gottwald, Bernd Salzberger, Ralf Wagner, Florian Zeman et al. · 2021 · Infection
  99. COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review
    Faizan Zarreen Simnani, Dibyangshee Singh, Ramneet Kaur · 2021 · 3 Biotech
  100. Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera
    Samuel J. Vidal, Ai-ris Yonekura Collier, Jingyou Yu, Katherine McMahan, Lisa H. Tostanoski, John D. Ventura, Malika Aïd, Lauren E. Peter, Catherine Jacob-Dolan, Tochi Anioke et al. · 2021 · Journal of Virology